A Pilot Prospective Clinical Trial to Use Pharmacogenetics (PGx) to Select Erbitux or Cisplatin to Treat Head and Neck Cancer

Trial Profile

A Pilot Prospective Clinical Trial to Use Pharmacogenetics (PGx) to Select Erbitux or Cisplatin to Treat Head and Neck Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2013

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 01 Jun 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 20 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top